Treatment News : ‘Quad’ Comparable to Norvir-Reyataz Regimen in Phase III Study - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 13, 2012

‘Quad’ Comparable to Norvir-Reyataz Regimen in Phase III Study

by Tim Horn

CROI 2012 A study of Gilead Sciences’ “Quad” fixed-dose combination tablet containing the experimental integrase inhibitor elvitegravir and boosting agent cobicistat, along with tenofovir and emtricitabine, has met its primary objective—“non-inferiority” compared with the popular protease inhibitor–based regimen of Norvir (ritonavir)-boosted Reyataz (atazanavir) plus Truvada (tenofovir and emtricitabine)—according to data presented Thursday, March 8, at the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

According to Gilead Study 103 principle principal investigator, Edwin DeJesus, MD, of the Orlando Immunology Center and his colleagues, 90 percent of those who took the Quad tablet in the study had undetectable viral loads (less than 50 copies) after 48 weeks of treatment, compared with 87 percent of those who took the Reyataz-inclusive regimen.

Study 103 is one of two Phase III clinical trials comparing the Quad to with a standard HIV treatment regimen in people living with HIV starting therapy for the first time. Results from Study 102, which compared the Quad to with Atripla (efavirenz plus tenofovir and emtricitabine), were also reported at CROI.

Though the primary goals of the studies is to compare rates of undetectable viral loads after 48 weeks of therapy, both trials plan to follow patients participants on their assigned treatment regimens for at least three and a half years.

At the start of Study 103, the 708 patients enrolled had an average viral load of 75,000 copies and CD4 counts of 370 cells. Approximately About 41 percent had viral loads in excess ofover 100,000 copies, and 13 percent had CD4 counts of 200 or below. Ninety percent were male, and 26 percent were non-white.

The difference in the rates of undetectable viral loads at week 48 was not statistically significant and within 12 percent of each other, hence the Quad regimen was concluded to be “non-inferior” to Norvir-boosted Reyataz plus Truvada.

DeJesus and his colleagues also noted comparable efficacy in patients who started patients with high viral loads—a pre-treatment factor that has rendered some ARV regimens more effective than others. Among those with baseline viral loads above 100,000, 85 percent of those in the Quad group, compared with 82 percent of those in the Reyataz group, had viral loads below 50 copies after 48 weeks.

Thus far, five 5 percent of patients in both groups have experienced virologic failure—either an inability to get their viral loads undetectable or a rebound in viral load following an undetectable reading—while on their respective regimens.

Gains in CD4 counts were similar in the two groups, with a 207-cell gain in the Quad group and a 211-cell gain in the Reyataz group.

Patients in both arms experienced similar increases in CD4 cell counts (a mean increase of 207 cells/mm3 for Quad and 211 cells/ mm3 for ATV/r plus Truvada). The virologic failure rate was 5 percent for both treatment regimens based on a component of the FDA snapshot analysis.
Common side effects, with no significant differences between the two groups, includined included diarrhea, nausea, headache, fatigue and upper respiratory tract infections. Ocular icterus—yellowing of the eyes; associated with increased bilirubin levels levels—was more common in the Reyataz group (14 percent) compared with those in the Quad group (1 percent).

As for laboratory abnormalities, the only statistically significant differences including included higher bilirubin and triglyceride levels, and both of those occurred in the Reyataz group. Increases in creatinine levels—a marker of kidney function—increased in both groups (0.12 milligrams per deciliter [mg/dL] in the Quad group and 0.08 mg/dL in the Reyataz group), but this difference was not statistically significant.

DeJesus and his colleagues also conducted bone mineral density comparisons, which showed decreases in hip measurements and an increase (Quad) and decrease (Reyataz) in spine measurements. The noted differences, however, were not statistically significant.

The discontinuation rate due to side effects was higher in the Norvir-boosted Reyataz group (5.1 percent) compared with the Quad group (3.1 percent). This difference was driven primarily by elevated bilirubin levels in the Norvir-boosted Reyataz group. Though increased bilirubin can also be a sign of liver toxicity, this does not appear to be any more common among people taking Norvir-boosted Reyataz.

“Quad demonstrated non-inferior efficacy and was well tolerated at 48 weeks in this Phase III blinded, active-controlled study in treatment-naïve HIV-infected subjects,” DeJesus and his colleagues concluded. “These data support the use of Quad as a potential new single-tablet regimen option for initial HIV treatment,” he added, alluding to the anticipated FDA approval of the drug at the end of August 2012.

Search: Quad, elvitegravir, cobicistat, tenofovir, emtricitabine, reyataz, atazanavir, integrase inhibitor, treatment naive, fixed-dose combination, fdc, phase III, DeJesus, CROI, 2012


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    aqua_31206
    Macon
    Georgia


    juliar33
    brooklyn
    New York


    latinpozdallas
    Dallas
    Texas


    jap022964
    el dorado
    Arkansas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.